Characteristics of HPRT-mutant T cell lines in a lupus patient treated with cyclophosphamide.
This report describes T cell lines derived from a patient with subacute cutaneous lupus after treatment with intravenous pulse cyclophosphamide. We selected for mitotically active, hypoxanthine-guanine phosphoribosyltransferase-deficient (HPRT-) T cells, by culture in a selective medium containing 6-thioguanine. When HPRT- cell lines were derived 6 days after pulse cyclophosphamide (CYC) treatment, they were predominantly CD8+ and T cell receptor (TCR) gamma/delta+, producing interferon-gamma (IFN gamma). Cell lines derived 21 days after CYC treatment were CD4+, TCR alpha/beta+ and produced both IFN gamma and interleukin-4. These results support a possible role for gamma/delta+ T cells in subacute cutaneous lupus and suggest a mechanism for the therapeutic effect of CYC.
Wood
G M
GM
National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH, Bethesda, Maryland 20892.
Dawisha
S
S
Gourley
M
M
D000328:Adult; D015496:CD4-Positive T-Lymphocytes / Q000737:chemistry / Q000473:pathology*; D018414:CD8-Positive T-Lymphocytes / Q000737:chemistry / Q000473:pathology*; D002460:Cell Line; D003520:Cyclophosphamide / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D007041:Hypoxanthine Phosphoribosyltransferase / Q000172:deficiency*; D007262:Infusions, Intravenous; D008180:Lupus Erythematosus, Systemic / Q000188:drug therapy / Q000473:pathology*; D009154:Mutation; D011948:Receptors, Antigen, T-Cell / Q000032:analysis
D011948:Receptors, Antigen, T-Cell; D003520:Cyclophosphamide; D007041:Hypoxanthine Phosphoribosyltransferase